首页> 外文期刊>Molecular and Cellular Biochemistry: An International Journal for Chemical Biology >Effect of RNAi-induced down regulation of nuclear factor kappa-B p65 on acute monocytic leukemia THP-1 cells in vitro and vivo.
【24h】

Effect of RNAi-induced down regulation of nuclear factor kappa-B p65 on acute monocytic leukemia THP-1 cells in vitro and vivo.

机译:RNAi诱导下调核因子κBp65对急性单核细胞白血病THP-1细胞的体内和体外作用。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

NF-kappaB p65 is found constitutively active in acute monocytic leukemia, and has been considered an important factor for poor prognosis. Therefore, develop specifically target p65 inhibitors will be substantial interest. Until now, although several p65 inhibitors are currently in preclinical and clinical development, none of them are targeting. In this study, siRNA targeting p65 was introduced into the acute monocytic leukemia cell line THP-1 and THP-1 xenograft tumors in nude mice, and then, we measured p65 mRNA and protein levels by real-time RT-PCR and Western blotting, and levels of related protein cyclin D1, Bc1-2, and SMRT by Western blotting. We also investigated the cell cycle and apoptosis via FCM, and cell proliferation by Cell Counting Kit-8 assay. We found that p65 siRNA could effectively reduce the p65 mRNA and protein expression, arrest cells in G0/G1 phase, inhibit the proliferation and increase the apoptosis of THP-1 cells, and intratumoral injection of p65 siRNA could suppress tumor growth in nude mice. We also found that when down regulation of p65, the expression of cyclin D1 and Bc1-2 decreased, and the expression of SMRT increased in vitro and vivo. All these findings suggest that NF-kappaB p65 maybe an attractive candidate for the therapeutic targeting of acute monocytic leukemia.
机译:NF-κBp65在急性单核细胞白血病中具有组成性活性,并且被认为是预后不良的重要因素。因此,开发专门针对靶标的p65抑制剂将引起广泛关注。到目前为止,尽管目前有几种p65抑制剂正在临床前和临床开发中,但它们都不是靶向药物。在这项研究中,将靶向p65的siRNA引入裸鼠的急性单核细胞白血病细胞THP-1和THP-1异种移植肿瘤中,然后通过实时RT-PCR和Western印迹法测量p65 mRNA和蛋白水平, Western blot检测相关蛋白cyclin D1,Bc1-2和SMRT的水平。我们还研究了通过FCM进行的细胞周期和细胞凋亡,以及通过Cell Counting Kit-8分析的细胞增殖。我们发现p65 siRNA可以有效降低p65 mRNA和蛋白表达,将细胞阻滞在G0 / G1期,抑制THP-1细胞的增殖并增加其凋亡,瘤内注射p65 siRNA可以抑制裸鼠的肿瘤生长。我们还发现,当下调p65时,在体内和体外,cyclin D1和Bc1-2的表达降低,而SMRT的表达增加。所有这些发现表明,NF-κBp65可能是急性单核细胞白血病靶向治疗的诱人候选物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号